X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (130) 130
gastroenterology and hepatology (115) 115
index medicus (100) 100
gastroenterology & hepatology (89) 89
male (83) 83
female (82) 82
middle aged (74) 74
adult (69) 69
hepatitis c (66) 66
hepatitis c, chronic - drug therapy (57) 57
ribavirin (55) 55
drug therapy, combination (50) 50
hepatitis c virus (50) 50
interferon (50) 50
aged (44) 44
hepacivirus - genetics (44) 44
treatment outcome (40) 40
hepatitis (38) 38
genotype (37) 37
antiviral agents - therapeutic use (36) 36
cirrhosis (36) 36
antiviral agents - administration & dosage (33) 33
genetic aspects (33) 33
health aspects (33) 33
antiviral agents - adverse effects (31) 31
ribavirin - therapeutic use (31) 31
hepatitis c, chronic - virology (30) 30
care and treatment (29) 29
virus-infection (28) 28
ribavirin - administration & dosage (27) 27
liver cirrhosis (26) 26
ribavirin - adverse effects (26) 26
telaprevir (25) 25
antiviral agents (24) 24
therapy (24) 24
abridged index medicus (23) 23
analysis (22) 22
drug therapy (21) 21
interferon-alpha - therapeutic use (21) 21
medicine, general & internal (20) 20
viral load (20) 20
adolescent (19) 19
genotype & phenotype (19) 19
infectious diseases (19) 19
transplantation (19) 19
young adult (19) 19
liver (18) 18
pharmacology & pharmacy (18) 18
plus ribavirin (18) 18
sofosbuvir (18) 18
virology (18) 18
chronic hepatitis-c (17) 17
double-blind method (17) 17
infection (17) 17
interferon-alpha - administration & dosage (17) 17
time factors (17) 17
boceprevir (16) 16
hepacivirus - drug effects (16) 16
interferon-alpha - adverse effects (16) 16
pegylated interferon (16) 16
polyethylene glycols - administration & dosage (16) 16
proline - analogs & derivatives (16) 16
protease inhibitors (16) 16
clinical trials (15) 15
medical colleges (15) 15
polyethylene glycols - therapeutic use (15) 15
proteases (15) 15
genotypes (14) 14
infections (14) 14
medical research (14) 14
risk factors (14) 14
virus diseases (14) 14
anemia (13) 13
biological response modifiers (13) 13
combination (13) 13
hcv (13) 13
hepatitis c, chronic - complications (13) 13
polyethylene glycols - adverse effects (13) 13
rna, viral - blood (13) 13
article (12) 12
biological products industry (12) 12
dosage and administration (12) 12
hepacivirus - isolation & purification (12) 12
hepatitis c - drug therapy (12) 12
hepatology (12) 12
life sciences (12) 12
liver transplantation (12) 12
medicine, experimental (12) 12
recombinant proteins (12) 12
retreatment (12) 12
surgery (12) 12
sustained virological response (12) 12
fibrosis (11) 11
patients (11) 11
peginterferon alpha-2b (11) 11
recombinant proteins - administration & dosage (11) 11
recombinant proteins - adverse effects (11) 11
retrospective studies (11) 11
sustained virologic response (11) 11
united states (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 13, pp. 1195 - 1206
Journal Article
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
Journal Article
Hepatology, ISSN 0270-9139, 03/2013, Volume 57, Issue 3, pp. 974 - 984
Journal Article